The Pyrrhonic Sceptics in ancient Greece employed a useful catchword, epoche ('suspension of judgment'), in philosophic argument. ' The expression serves admirably to summarise the current state of knowledge concerning the unique retinopathy that affects prematurely born infants. There are renewed, intense debates about pathophysiological mechanisms that may lead to retinopathy of prematurity, and there is now general agreement that we have been unable to devise a reliable plan to prevent occurrence of the potentially blinding disorder.
Active stages newly classified
Improved techniques for examining the ocular fundus-for example, binocular indirect ophthalmoscopy, fluoroscein angiography, and retinal photography2 3-have, in recent years, provided a new perspective on the retinal changes that occur in retinopathy of prematurity. It became clear that the 1953 classification scheme,4 based on the relatively restricted view of premature infants' fundi through the direct ophthalmoscope, was inadequate, and, by 1981, a pressing need to obtain general agreement on a modern classification was recognised. 5 In 1982 a group of ophthalmologists from I 1 countries met in Calgary, Canada, to begin work on a revised system. The final schema was published in mid-19846 after each of those who had attended the conference had had an opportunity to use the proposal to classify retinal changes in newly affected patients seen in their institutions over a period of one year.
The international classification (tagged. predictably, with a euphonious acronym-ICROP) introduces two new axes of categorisation: the location of disease in the retina and the extent of the developing retinal vessels involved in the pathological process. For the purpose of localisation, the retinal field of each eye is divided into three concentric zones oriented around the optic disc. The extent of involvement in each eye is specified by hours of the clock. Severity of active retinopathy, in designated zones and of indicated extent, is ranked in four stages, beginning with recognition of a definite demarcation line that separates avascular from vascularised retina (stage 1) through progressive changes that may end with unequivocal retinal detachment (stage 4). The fundal changes are recorded on a form that consists of a 'map' drawing of the retina of each eye that indicates three zones and clock hours. The disease stage assigned to each eye is based on the most severe manifestation at the time of the current examination.
Publication of the ICROP proposal focuses attention on the problem of uniformity of diagnoses; the accomplishment of the international group of ophthalmologists raises expectations that there will be improvement in the quality of observations in future comparative studies of prevention and treatment of retinopathy of prematurity. There is now hope that investigators will include analyses of reproducibility and of observer variation of eye examinations in reports of clinical trials. And there is the possibility that the ICROP 'yardstick' will be used in comparing experiences between localities and in the same institutions over time.
Cooperative efforts are now under way to reexamine classification of the stages in retrolental fibroplasia (this old term is appropriate as a description of the late changes in severely affected infants). The new scheme of coding retinal damage will attempt to reconcile two considerations: the visual potential of the eye and the potential for surgical treatment. The final proposal will complete the difficult task and welcome goal of formulating an up to date diagnostic standard of retinopathy of prematurity for international use; it should be available before too long. Epoche in retinopathy of prematuritv 523 central nervous system (CNS), and septic states that accompany the retinopathy in many extremely premature neonatal patients. "
Dependable animal models are urgently needed to explore, at some depth, the numerous interventions that have been proposed over the years to prevent or to treat the human eye disease. Very few of the agents brought to notice in the past were tested rigorously. Looking back, we can see now that most of the planned clinical studies conducted in the 1940s and 5(s for example, correction of vitamin E deficiency, reduced exposure to light, or withholding transfusions of adult blood-were much too small to rule out important effects. I will return to the issue of the numbers of observations below.
The vitamin E debate
The hope that vitamin E prophylaxis would eliminate retinopathy of prematurity has waxed and waned since the late 1940s. In recent years the proposition has been subjected to a number of randomised clinical trials, but a convincing answer has yet to be vouchsafed. ' The vitamin E:retinopathy of prematurity relation has been given new prominence because of Kretzer's intriguing observaitions of the ultrastructure of the developing retina in infants supplemented with vitamin E aind others not supplemented with vitamin E who died in the neonatal period. '7 On the basis of these observations, he has erected at testable thesis that specifies initial spindle cell in'jury from alterations in oxygen tension (intrauterine hypoxia, or postnatal hyper-or hypoxia), increase in gap junctions between adjacent injured spindle cells, increase in cytoplasmic volume of rough endoplasmic reticulum within spindle cells and subsequent decrease of volume with the down modulation of gap junctions, a period of synthesis and secretion of angiogenic factors (only found in extracts of the vanguard retina of infants who did not receive vitamin E supplements), and, finally, invasion of myofibroblasts into the vitreous. The hypothesis also provides an explanation for the purported lack of efficacy of vitamin E in infants 627 weeks' gestational age (due to the complex relation between an interstitial retinol binding protein, which transports fat soluble substances across the polar subretinal space, and the developmental position in the retina of outwardly migrating spindle cells). If this fascinating concept of pathogenesis survives attempts to replicate the observations and rigorous experiments to test the postulated mechanisms it will go a long way in unravelling the mysteries of retinopathy of prematurity.
An ablative cryotherapy trial
The most encouraging development about surgical intervention to halt progression of proliferating retinal changes is a general acknowledgment that the most promising approach, ablative cryotherapy, needs to be formally tested to determine the procedure's limits of usefulness. A multicentre randomised clinical trial has been designed to take advantage of the known tendency of retinopathy of prematurity to progress symmetrically.'8 In most enrolled infants, therefore, one eye will be treated with experimental cryotherapy while the fellow eye is to be observed as a control. When there is asymmetric involvement-that is, only one eye progresses to meet the eligibility criteria, expected in about 20% of cases-patients themselves are to be assigned in random order to treatment or control groups. The design assures that no patient will receive the unevaluated treatment to both eyes afflicted with the notoriously capricious disorder. The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP is the almost pronounceable acronym here) is now under way. (With 30% of infants affected by retinopathy of prematurity expected to suffer a visually unfavourable outcome and a postulated 35% reduction in this risk rate, roughly 300 infants will be required to ensure that an outcome difference of this magnitude will be detected with 80% power and a Type 1 error set at 5%.) There is every reason to hope that interpretable results will be available in the next few years.
Multinational cooperation?
One of the great difficulties that has plagued those interested in putting an end to the threat of retinopathy of prematurity is that of accumulating sufficient numbers of extremely premature at risk infants for formal studies of the disorder. Chalmers and Sinclair have pointed out that the problem of small sample sizes is common to all perinatal studies. '9 They warn of two potential consequences when comparative studies are too small. Firstly, real and clinically important differences between treatments may be incorrectly dismissed because they fail to achieve significance. Secondly, if significant differences are observed these will tend to result in an overestimate of true differences.
As renewed interest in retinopathy of prematurity grows and the inevitable increase in number of treatment proposals-for example, use of antioxidants, indomethacin, or antenatal betamethasone; reduced exposure to light; vitrectomy . -compete for the attention of perplexed caretakers it would be well to keep in mind that the duration of confusion can be reduced by cooperative action. For example, success of the international effort to reclassify retinopathy of prematurity might lead the way to collective experiences of the kind recently reported by neurosurgeons in 71 centres on three continents.2t' The latter specialists have shown that the multinational trial is an acceptable, believable, and scientifically necessary method to obtain large enough numbers of patients to answer important therapeutic questions in a reasonable period of time. 
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